Drug Profile
Caldaret
Alternative Names: MCC-135Latest Information Update: 25 May 2010
Price :
$50
*
At a glance
- Originator Mitsubishi Chemical
- Class Anti-ischaemics; Benzenesulfonates; Heart failure therapies; Piperazines; Small molecules
- Mechanism of Action Sodium-calcium exchanger inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myocardial infarction
Most Recent Events
- 12 May 2010 Discontinued - Phase-II for Myocardial infarction in European Union (IV)
- 12 May 2010 Discontinued - Phase-II for Myocardial infarction in USA (IV)
- 01 Oct 2007 Mitsubishi Pharma Corporation merged with Tanabe Seiyaku Co. Ltd to form Mitsubishi Tanabe Pharma Corporation